Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.67 |
| ▸ | TGM2 | P21980 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.60 |
| ▸ | CCR6 | P51684 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.58 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.58 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.58 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.58 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4373055 | 1.00 | HTT (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL7877730 | 0.92 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL4211608 | 0.92 | ALDH1A1 (0.58) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9340146 | 0.91 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL15346534 | 0.91 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL9874334 | 0.91 | HTT (0.79) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL13706605 | 0.90 | MEN1 (0.58) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL13365569 | 0.89 | LMNA (0.67) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL1299850 | 0.89 | HTT (0.72) | HTTTGM2LMNASMN1; SMN2KEAP1 | |
| SCHEMBL18254066 | 0.89 | HTT (0.81) | HTTTGM2LMNASMN1; SMN2KEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | JOHNSON MICHAEL ROSS (US) | 2013-03-07 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | ADRB1, ADRB2, ADRA2B | HTT 3640/4885TGM2 4506/4885LMNA 1309/4885 |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | SCNN1G, SCNN1B, TRPV1 | HTT 3451/4885TGM2 2668/4885LMNA 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.